BDKRB1 and early-onset autosomal dominant Alzheimer disease: Evaluation of Novel B1R/B2R Agonists Containing TRIOZANTM Nanoparticles for Targeted Brain Delivery of Antibodies in a Mouse Model of Alzheimer Disease